Paper40407381
KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.
Kijima T and 11 others. Cancer Sci, 2025. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma. Papers, record 40407381. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40407381
- Disease
- pleural mesothelioma28 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal, Humanized | Major topic |
| Pemetrexed | Major topic |
| Cisplatin | Major topic |
| Pleural Neoplasms | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Mesothelioma | Major topic |
| Humans | |
| Male | |
| Female | |
| Middle Aged | |
| Aged | |
| Adult | |
| Japan | |
| Mesothelioma, Malignant | |
| East Asian People |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04153565 | A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17) | Results | Yes |
Source ClinicalTrials.gov
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29282508 | A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma. | World J Surg | 2018 | https://conductscience.org/library/papers/29282508 | PubMed |
| 2 | 32206576 | Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. | Transl Lung Cancer Res | 2020 | https://conductscience.org/library/papers/32206576 | PubMed |
| 3 | 36841541 | Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171). | J Thorac Oncol | 2023 | https://conductscience.org/library/papers/36841541 | PubMed |
| 4 | 33836153 | Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. | Lancet Respir Med | 2021 | https://conductscience.org/library/papers/33836153 | PubMed |
| 5 | 12860938 | Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/12860938 | PubMed |
| 6 | 31487687 | Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2019 | https://conductscience.org/library/papers/31487687 | PubMed |
| 7 | 34036692 | Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study. | Cancer Sci | 2021 | https://conductscience.org/library/papers/34036692 | PubMed |
| 8 | 35124183 | First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. | Ann Oncol | 2022 | https://conductscience.org/library/papers/35124183 | PubMed |
| 9 | 30267842 | Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. | J Thorac Oncol | 2018 | https://conductscience.org/library/papers/30267842 | PubMed |
| 10 | 22438785 | Mesothelioma: a review. | Ochsner J | 2012 | https://conductscience.org/library/papers/22438785 | PubMed |
| 11 | 37931632 | Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. | Lancet | 2023 | https://conductscience.org/library/papers/37931632 | PubMed |
| 12 | 14760119 | Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. | Ann Oncol | 2004 | https://conductscience.org/library/papers/14760119 | PubMed |
| 13 | 34589998 | Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study. | JTO Clin Res Rep | 2021 | https://conductscience.org/library/papers/34589998 | PubMed |
| 14 | 18434338 | Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients. | Jpn J Clin Oncol | 2008 | https://conductscience.org/library/papers/18434338 | PubMed |
| 15 | 17715248 | Dose-finding in phase I clinical trials based on toxicity probability intervals. | Clin Trials | 2007 | https://conductscience.org/library/papers/17715248 | PubMed |
| 16 | 28291584 | Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28291584 | PubMed |
| 17 | 34711664 | JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/34711664 | PubMed |
| 18 | 28239496 | Life Expectancy in Pleural and Peritoneal Mesothelioma. | Lung Cancer Int | 2017 | https://conductscience.org/library/papers/28239496 | PubMed |
| 19 | 29342862 | Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/29342862 | PubMed |
| 20 | 34750557 | Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. | Nat Med | 2021 | https://conductscience.org/library/papers/34750557 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42236311 | Orthogonal Chemistry Enables Precision Nanoparticle Cofunctionalization for Tuning Immune Stimulation and Antigen Presentation. | Biomacromolecules | 2026 | https://conductscience.org/library/papers/42236311 | PubMed |
| 41696561 | Immunotherapy advances in pleural mesothelioma. | Ther Adv Med Oncol | 2026 | https://conductscience.org/library/papers/41696561 | PubMed |
| 41342969 | Immunotherapy for pleural mesothelioma: from innovation to the frontlines of core clinical questions. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41342969 | PubMed |
| 41228239 | Obesity and Metabolic Syndrome in Childhood Leukemia and in Long-Term Survivors: Causes and Personalized Treatments. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228239 | PubMed |
| 40481943 | PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of belantamab mafodotin for multiple myeloma, asciminib for leukemia, osimertinib for lung cancer, amivantamab for lung cancer, and pembrolizumab for pleural mesothelioma in Japan. | Int J Clin Oncol | 2025 | https://conductscience.org/library/papers/40481943 | PubMed |
Drugs3
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL11359 | ChEMBL |
| PEMETREXED | CHEMBL225072 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL225072 | ChEMBL |
| PEMBROLIZUMAB | CHEMBL3137343 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL3137343 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40407381
GET https://conductscience.org/api/papers/v1/40407381/references?page=2